Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study.

Fecha de publicación: 01/05/2021 Fecha Ahead of Print: 16/02/2021

Autores de IIS La Fe

Jorge Aparicio Urtasun

Autor

Participantes ajenos a IIS La Fe

Longo F
Jorge M
Yaya R
Montes AF
Lago NM
Brozos E
Quintero G
Ceballos E
Buxó E
Lopez AM
Pellón ML
Molina R
Diaz-Paniagua L
Cerdà P
Leiva PL
Carnicero AM
Cousillas A
Paris L
García-Paredes B
Romero C
Ortega M
Molero A
la Torre S
Jen MH
Díaz-Cerezo S

Grupos

Investigación Clínica y Traslacional en Cáncer

Leader

José Gómez Codina

Abstract

Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). M ethods: Observational, retrospective study carried out in 20 Spanish hospitals, in patients who started ramucirumab treatment between December 2015 and December 2018. Descriptive analysis was conducted for patient characteristics, treatment patterns and effectiveness outcomes. Results: Three hundred seventeen patients were included (93.7% treated with ramucirumab-paclitaxel and 6.3% with ramucirumab); age 62.5 (11.3) years; 66.9% male. Median progression-free survival and overall survival were 3.9 months (95% CI: 3.4-4.3) and 7.4 (95% CI: 6.4-8.9) in combination regimen and 2.0 (1.1-2.8) and 4.3 (95% CI: 1.9-7.3) in monotherapy, respectively. Conclusion: The study findings were consistent with available real-world studies and randomized clinical trials.

Datos de la publicación

ISSN/ISSNe:: 1479-6694, 1744-8301
Tipo:: Article
Páginas:: 1777-1791
DOI:: 10.2217/fon-2020-1216
PubMed:: 33590772
Factor de Impacto:: 0,836 SCImago ℠
Cuartil:: Q2 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Keywords

effectiveness, gastric cancer/GEJ adenocarcinoma, ramucirumab, real-world data, treatment patterns

Campos de Estudio

Cita

Cita Bibliográfica